Page last updated: 2024-12-07

vitamin k1 oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

vitamin K1 oxide: RN given refers to parent cpd; see also record for 2,3-epoxymenaquinone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280845
CHEMBL ID299632
SCHEMBL ID1228274
MeSH IDM0066012

Synonyms (25)

Synonym
vitamin k1, epoxide
vitamin k 2,3-epoxide
C05849
vitamin k1 oxide
phylloquinone epoxide
(2,3-epoxyphytyl)menaquinone
phylloquinone oxide
vitamin k1 2,3-epoxide
vitamin k1 epoxide
phylloquinone-2,3-epoxide
1a,7a-dihydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecenyl)-naphth[2,3-b]oxirene-2,7-dione
25486-55-9
1a-methyl-7a-(3,7,11,15-tetramethylhexadec-2-en-1-yl)-1a,7a-dihydronaphtho[2,3-b]oxirene-2,7-dione
CHEMBL299632
7a-methyl-1a-[(e)-3,7,11,15-tetramethylhexadec-2-enyl]naphtho[2,3-b]oxirene-2,7-dione
phylloquinone 2,3-epoxide
1a,7a-dihydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecen-1-yl)-naphth[2,3-b]oxirene-2,7-dione
SCHEMBL1228274
naphth[2,3-b]oxirene-2,7-dione, 1a,7a-dihydro-1a-methyl-7a-(3,7,11,15-tetramethyl-2-hexadecenyl)-
1a-methyl-7a-[3,7,11,15-tetramethyl-2-hexadecenyl]-1a,7a-dihydronaphtho[2,3-b]oxirene-2,7-dione #
KUTXFBIHPWIDJQ-LKUDQCMESA-N
1,4-naphthoquinone, 2,3-epoxy-2,3-dihydro-2-methyl-3-phytyl-
vitamin k1 2,3-epoxide, >=98.0% (hplc)
DTXSID80904572
trans-epoxyphytomenadione

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In group I, the plasma half-life of the first component was between 18 and 52 min (median 23 min), and the half-life of the second was between 67 and 179 min (median 109 min)."( Pharmacokinetics of vitamin K1 in low-birth-weight neonates.
Bethenod, M; Bourgeay-Causse, M; Bourgeois, J; Frederich, A; Leclercq, M; Sann, L, 1985
)
0.27

Bioavailability

ExcerptReferenceRelevance
" However, the bioavailability of vitamin K1 after administration of MM-K was poor (9."( The bioavailability of a mixed micellar preparation of vitamin K1, and its procoagulant effect in anticoagulated rabbits.
Park, BK; Pratt, SK; Scott, AK; White, PM; Winn, MJ, 1989
)
0.28
"This randomized, controlled study evaluated the bioavailability of phylloquinone from an intravenous lipid emulsion."( Bioavailability of phylloquinone from an intravenous lipid emulsion.
Camilo, ME; Davidson, K; Jatoi, A; Mason, JB; O'Brien, M; Sadowski, JA; Sokoll, L, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
"A proper dosage of warfarin after artificial cardiac valve replacements has been determined as an indication of coagulation activity."( Variations in warfarin concentration in blood and coagulant factors after artificial valve replacement.
Ishibashi, M; Kariyazono, H; Nakamura, K; Shimokawa, S; Taira, A; Toyohira, H, 1992
)
0.28
"Patients (40 cases) were treated with daily dosage of warfarin of 2-7 mg after being undergone artificial valve replacements."( Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces.
Ishibashi, M; Kariyazono, H; Nakamura, K; Saigenji, H; Shimokawa, S; Taira, A; Toyohira, H, 1994
)
0.29
" Correlation analysis of data showed that warfarin dosage was significantly and negatively correlated with patient age (r = -0."( The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
Butler, TJ; Edwards, C; Kamali, F; Wynne, HA, 2000
)
0.31
" The predicted warfarin-binding site was verified by shifted dose-response curves of specified mutated residues."( Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Biswas, A; Czogalla, KJ; Höning, K; Hornung, V; Liphardt, K; Oldenburg, J; Watzka, M, 2017
)
0.46
" Despite being at risk for VKDB, there are no studies comparing vitamin K versus non-treatment and few studies that address potential dosing strategies for effective treatment."( Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates.
Ardell, S; Offringa, M; Ovelman, C; Soll, R, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
blood coagulationVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
peptidyl-glutamic acid carboxylationVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
vitamin K metabolic processVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
bone developmentVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
vitamin-K-epoxide reductase (warfarin-sensitive) activityVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
quinone bindingVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneVitamin K epoxide reductase complex subunit 1 Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID217147Vmax value at Vitamin K epoxide reductase1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Substituted vitamin K epoxide analogues. New competitive inhibitors and substrates of vitamin K1 epoxide reductase.
AID217145Km value at Vitamin K epoxide reductase1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Substituted vitamin K epoxide analogues. New competitive inhibitors and substrates of vitamin K1 epoxide reductase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (107)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (45.79)18.7374
1990's28 (26.17)18.2507
2000's14 (13.08)29.6817
2010's14 (13.08)24.3611
2020's2 (1.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (5.50%)5.53%
Reviews9 (8.26%)6.00%
Case Studies6 (5.50%)4.05%
Observational0 (0.00%)0.25%
Other88 (80.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]